China-based Gan & Lee Pharmaceuticals (SHA: 603087) has announced plans to raise up to RMB 814 million (USD 111.4 million) through a private placement. The funds raised will be used as supplementary working capital to support the company’s operations and strategic initiatives.
Shareholding Structure and Company Valuation
Mr. Gan Zhongru, the controlling shareholder, actual controller, and chairman of the board of directors of Gan & Lee Pharmaceuticals, directly holds 177,135,200 shares, accounting for 31.54% of the total shares before the non-public offering. Additionally, he indirectly controls an 8.46% stake in the company through Beijing Xute Hongda Technology Co., Ltd. In total, Mr. Gan holds 40.00% of the company’s equity. As of the announcement date, Gan & Lee Pharmaceuticals is valued at RMB 19.1 billion (USD 2.6 billion).
Future Outlook
The private placement is expected to enhance the company’s liquidity and financial flexibility, supporting its ongoing business activities and future growth plans. This move underscores Gan & Lee Pharmaceuticals’ commitment to strengthening its capital base and ensuring sustainable development in the competitive pharmaceutical market.-Fineline Info & Tech
